Activities of Transmitted/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release

Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodef...

Full description

Saved in:
Bibliographic Details
Published inJournal of virology Vol. 88; no. 9; pp. 5062 - 5078
Main Authors Jafari, Moein, Guatelli, John, Lewinski, Mary K.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.05.2014
Subjects
Online AccessGet full text
ISSN0022-538X
1098-5514
1098-5514
DOI10.1128/JVI.03472-13

Cover

Abstract Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIV cpz ) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the “transmitted/founder” (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse “quasispecies” of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. IMPORTANCE To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission (“transmitted/founder” viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.
AbstractList Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIV cpz ) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the “transmitted/founder” (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse “quasispecies” of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. IMPORTANCE To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission (“transmitted/founder” viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.
Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.
Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.UNLABELLEDAcute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu.To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.IMPORTANCETo establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.
Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract these factors, and one such adaptation, the ability of Vpu to counteract BST2/tetherin, is associated with the evolution of simian immunodeficiency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1). During transmission between individuals, very few viruses or even a single virus, the "transmitted/founder" (T/F) virus, gives rise to the new infection, but in the new host the selective pressure of the immune response yields the diverse "quasispecies" of chronic infection. Here we examine the functional characteristics of Vpu proteins encoded by T/F viruses compared to acute and chronic viruses from longitudinally sampled subjects. The studied T/F Vpu proteins showed a trend toward optimized CD4 downregulation compared to chronic Vpu proteins but did not differ substantially in their ability to downregulate BST2 or enhance virion release, although individual clones from each group were impaired in these activities. Analysis of the functionally impaired clones identified a C-terminal residue, W76, as important specifically for Vpu enhancement of virion release. Primary Vpu clones encoding a W76G polymorphism, or site-directed mutants encoding a W76G substitution, were impaired in their ability to enhance virion release, but they were not defective for BST2 surface downregulation. Conversely, the virion release function of impaired primary clones was restored by creating a G76W substitution. The identification of W76 as important for virion release enhancement that is independent of BST2 surface downregulation supports the potential to mechanistically separate these functions of Vpu. IMPORTANCE To establish infection in a host, HIV-1 must evade the host's immune response, including the production of antiviral factors. HIV-1 encodes proteins that antagonize these defenses, including Vpu. Vpu counteracts the host protein BST2, which blocks the release of progeny viruses from the host cell. To determine the importance of Vpu activity to HIV-1 transmission, this study assessed the functionality of Vpu from viruses isolated soon after transmission ("transmitted/founder" viruses) compared to isolates from chronic infection. Although the anti-BST2 activity of Vpu proteins from the tested transmitted/founder viruses did not differ from the activity of the chronic Vpu proteins, the transmitted/founder Vpu proteins trended toward having superior activity against another host protein, CD4. Further, this study identified an amino acid near the C terminus of Vpu that is specifically important for Vpu's ability to enhance the release of progeny virus from the host cell, supporting the notion of a new mechanism for this function of Vpu.
Author Guatelli, John
Jafari, Moein
Lewinski, Mary K.
Author_xml – sequence: 1
  givenname: Moein
  surname: Jafari
  fullname: Jafari, Moein
  organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA
– sequence: 2
  givenname: John
  surname: Guatelli
  fullname: Guatelli, John
  organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA, the VA San Diego Healthcare System, San Diego, California, USA
– sequence: 3
  givenname: Mary K.
  surname: Lewinski
  fullname: Lewinski, Mary K.
  organization: Department of Medicine, University of California, San Diego, La Jolla, California, USA, the VA San Diego Healthcare System, San Diego, California, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/24574397$$D View this record in MEDLINE/PubMed
BookMark eNqNkktv1DAURi1URKeFHWvkJQvS-pFMkg3SEFE6qBIIhhE7y7GvO0aOHeyk0qz7x-s-qACxYGVZ9_j42vc7Qgc-eEDoJSUnlLLm9ON2fUJ4WbOC8idoQUnbFFVFywO0IISxouLN90N0lNIPQmhZLstn6JCVVV3ytl6g65Wa7JWdLCQcDN5E6dNgpwn06VmYvYaIpde428XgrcKdkxrwO3y-3hYUb8f5ripxV2wgDtZLhz8Htx9CHHc2DfjrCMoaq6Rze7wyBvJt_hJvbbTB4y_gQCZ4jp4a6RK8eFiP0bez95vuvLj49GHdrS4KVTZ8KqRSSlJCOG3BsB76voeSqsrUrZbKNNoQTaUCYvqekkxw0oBmS920eddofoze3nvHuR9AK_BTlE6M0Q4y7kWQVvxZ8XYnLsOV4G3LG1ZnwesHQQw_Z0iTGGxS4Jz0EOYkaMUIbypCq_9A8yzYMksz-ur3th77-TWkDLy5B1QMKUUwjwgl4jYDImdA3GVA0Fsf-wtXdpJT_vD8KOv-fegGCES2yg
CitedBy_id crossref_primary_10_3390_v9100270
crossref_primary_10_1016_j_virol_2016_10_028
crossref_primary_10_1038_srep37225
crossref_primary_10_1016_j_jviromet_2016_11_004
crossref_primary_10_1128_JVI_02315_18
crossref_primary_10_1016_j_bbamem_2015_09_008
crossref_primary_10_1016_j_jbc_2021_101042
crossref_primary_10_1128_JVI_02736_15
crossref_primary_10_3389_fimmu_2017_01853
crossref_primary_10_3390_v7082824
crossref_primary_10_1073_pnas_1620144114
crossref_primary_10_3390_v14040808
crossref_primary_10_1128_mBio_00934_16
crossref_primary_10_1186_s12977_017_0343_8
crossref_primary_10_1128_JVI_01465_16
crossref_primary_10_1371_journal_pone_0120434
crossref_primary_10_3390_proteomes4010003
crossref_primary_10_1128_jvi_00176_22
crossref_primary_10_1016_j_celrep_2016_10_045
crossref_primary_10_3390_v14020406
crossref_primary_10_1128_JVI_00020_19
crossref_primary_10_1128_JVI_00504_16
crossref_primary_10_1038_srep09675
crossref_primary_10_1186_s12977_015_0192_2
crossref_primary_10_1371_journal_ppat_1005141
crossref_primary_10_1074_jbc_M114_630095
Cites_doi 10.1016/j.chom.2009.05.008
10.1016/S0960-9822(99)80284-X
10.1128/JVI.06157-11
10.1073/pnas.0813223106
10.1128/JVI.03219-12
10.1097/00002030-199010000-00008
10.1093/nar/18.12.3587
10.1006/jmbi.1994.1542
10.1074/jbc.M111.296772
10.1016/S1097-2765(00)80056-8
10.1089/hum.1995.6.10-1291
10.1128/JVI.00242-09
10.1128/JVI.02272-12
10.1371/journal.ppat.1000856
10.1371/journal.ppat.1000429
10.1006/viro.1996.0491
10.1128/JVI.02660-07
10.1128/JVI.78.3.1069-1079.2004
10.1073/pnas.1304288110
10.1128/JVI.01795-10
10.1016/j.chom.2008.03.001
10.1016/j.jviromet.2006.06.019
10.1371/journal.ppat.1003299
10.1128/JVI.05933-11
10.1056/NEJMoa1110187
10.1128/JVI.05524-11
10.1086/512088
10.1038/nature06553
10.1128/JVI.01699-10
10.1084/jem.20090378
10.1038/381661a0
10.1016/j.tim.2010.06.010
10.1128/jvi.70.2.809-819.1996
10.1128/JVI.01844-08
10.1073/pnas.0802203105
10.1016/j.jtbi.2009.07.038
10.1371/journal.ppat.1000450
10.1128/jvi.59.2.284-291.1986
10.1128/jvi.64.2.621-629.1990
10.1371/journal.ppat.1000574
10.1186/1742-4690-7-13
10.1074/jbc.M300327200
10.7326/0003-4819-152-12-201006150-00005
10.1128/JVI.03230-13
10.1016/j.chom.2009.10.004
10.1074/jbc.274.47.33800
ContentType Journal Article
Copyright Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
Copyright_xml – notice: Copyright © 2014, American Society for Microbiology. All Rights Reserved. 2014 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7T2
7U9
C1K
H94
5PM
DOI 10.1128/JVI.03472-13
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Health and Safety Science Abstracts (Full archive)
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Health & Safety Science Abstracts
Virology and AIDS Abstracts
Environmental Sciences and Pollution Management
DatabaseTitleList CrossRef
MEDLINE
MEDLINE - Academic
AIDS and Cancer Research Abstracts

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1098-5514
EndPage 5078
ExternalDocumentID PMC3993827
24574397
10_1128_JVI_03472_13
Genre Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIAID NIH HHS
  grantid: AI081668
– fundername: NIAID NIH HHS
  grantid: T32 AI007384
– fundername: NIAID NIH HHS
  grantid: P30 AI036214
– fundername: NIAID NIH HHS
  grantid: R37 AI081668
– fundername: NIAID NIH HHS
  grantid: AI036214
– fundername: NIAID NIH HHS
  grantid: P01 AI074621
– fundername: NIAID NIH HHS
  grantid: R01 AI081668
– fundername: NIAID NIH HHS
  grantid: AI74621
– fundername: NIAID NIH HHS
  grantid: R24 AI106039
GroupedDBID ---
-~X
.55
.GJ
0R~
18M
29L
2WC
39C
3O-
4.4
41~
53G
5GY
5RE
5VS
6TJ
85S
AAFWJ
AAGFI
AAYJJ
AAYXX
ABPPZ
ACGFO
ACNCT
ADBBV
ADXHL
AENEX
AFFNX
AGVNZ
AI.
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
D0S
DIK
E3Z
EBS
EJD
F5P
FRP
GX1
H13
HYE
HZ~
IH2
KQ8
MVM
N9A
O9-
OHT
OK1
P2P
RHI
RNS
RPM
RSF
TR2
UPT
VH1
W2D
W8F
WH7
WOQ
X7M
Y6R
YQT
ZGI
ZXP
~02
~KM
CGR
CUY
CVF
ECM
EIF
NPM
PKN
RHF
UCJ
7X8
7T2
7U9
C1K
H94
5PM
ID FETCH-LOGICAL-c483t-accca100319ef2bebbbe41c5f79dacf8df0d1ace0fbb10f2b308ed26d890f28d3
ISSN 0022-538X
1098-5514
IngestDate Thu Aug 21 13:48:23 EDT 2025
Fri Sep 05 14:28:14 EDT 2025
Fri Sep 05 10:07:13 EDT 2025
Wed Feb 19 02:42:35 EST 2025
Thu Apr 24 23:11:33 EDT 2025
Tue Jul 01 01:02:30 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c483t-accca100319ef2bebbbe41c5f79dacf8df0d1ace0fbb10f2b308ed26d890f28d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://jvi.asm.org/content/jvi/88/9/5062.full.pdf
PMID 24574397
PQID 1514426273
PQPubID 23479
PageCount 17
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_3993827
proquest_miscellaneous_1520385015
proquest_miscellaneous_1514426273
pubmed_primary_24574397
crossref_primary_10_1128_JVI_03472_13
crossref_citationtrail_10_1128_JVI_03472_13
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2014-05-01
PublicationDateYYYYMMDD 2014-05-01
PublicationDate_xml – month: 05
  year: 2014
  text: 2014-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Journal of virology
PublicationTitleAlternate J Virol
PublicationYear 2014
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_41_2
e_1_3_2_40_2
e_1_3_2_20_2
e_1_3_2_43_2
e_1_3_2_21_2
e_1_3_2_42_2
e_1_3_2_22_2
e_1_3_2_45_2
e_1_3_2_23_2
e_1_3_2_44_2
e_1_3_2_24_2
e_1_3_2_47_2
e_1_3_2_25_2
e_1_3_2_46_2
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_38_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_39_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_32_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_3_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_14_2
e_1_3_2_35_2
9660940 - Mol Cell. 1998 Mar;1(4):565-74
18342597 - Cell Host Microbe. 2008 Apr 17;3(4):245-52
20547906 - Ann Intern Med. 2010 Jun 15;152(12):778-85
8590733 - Hum Gene Ther. 1995 Oct;6(10):1291-7
16876264 - J Virol Methods. 2006 Oct;137(1):125-33
23323898 - N Engl J Med. 2013 Jan 17;368(3):218-30
19487424 - J Exp Med. 2009 Jun 8;206(6):1273-89
19196977 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73
19660475 - J Theor Biol. 2009 Nov 21;261(2):341-60
22190722 - J Virol. 2012 Mar;86(5):2715-28
10375528 - Curr Biol. 1999 Jun 17;9(12):622-31
14722262 - J Virol. 2004 Feb;78(3):1069-79
20926557 - J Virol. 2010 Dec;84(24):12958-70
21849457 - J Virol. 2011 Oct;85(20):10659-68
23325684 - J Virol. 2013 Mar;87(6):3549-60
18256145 - J Virol. 2008 Apr;82(8):3952-70
19501037 - Cell Host Microbe. 2009 Jul 23;6(1):54-67
23221546 - J Virol. 2013 Feb;87(4):2046-57
19917496 - Cell Host Microbe. 2009 Nov 19;6(5):409-21
19515779 - J Virol. 2009 Aug;83(16):7931-47
19176632 - J Virol. 2009 Apr;83(8):3719-33
18200009 - Nature. 2008 Jan 24;451(7177):425-30
24352444 - J Virol. 2014 Mar;88(5):2633-44
20386718 - PLoS Pathog. 2010 Apr;6(4):e1000856
10559275 - J Biol Chem. 1999 Nov 19;274(47):33800-6
7520946 - J Mol Biol. 1994 Sep 2;241(5):651-62
19478868 - PLoS Pathog. 2009 May;5(5):e1000450
22090097 - J Virol. 2012 Jan;86(2):757-72
18490657 - Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
2404139 - J Virol. 1990 Feb;64(2):621-9
23633949 - PLoS Pathog. 2013;9(4):e1003299
2194165 - Nucleic Acids Res. 1990 Jun 25;18(12):3587-96
8649511 - Nature. 1996 Jun 20;381(6584):661-6
23542380 - Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
3016298 - J Virol. 1986 Aug;59(2):284-91
8551619 - J Virol. 1996 Feb;70(2):809-19
8806575 - Virology. 1996 Sep 15;223(2):381-6
2261128 - AIDS. 1990 Oct;4(10):995-9
19730691 - PLoS Pathog. 2009 Sep;5(9):e1000574
19436700 - PLoS Pathog. 2009 May;5(5):e1000429
17330784 - J Infect Dis. 2007 Apr 1;195(7):951-9
20980512 - J Virol. 2011 Jan;85(1):51-63
20167081 - Retrovirology. 2010;7:13
20688520 - Trends Microbiol. 2010 Sep;18(9):388-96
22072710 - J Biol Chem. 2012 Jan 2;287(1):58-67
12746459 - J Biol Chem. 2003 Jul 25;278(30):28346-53
References_xml – ident: e_1_3_2_16_2
  doi: 10.1016/j.chom.2009.05.008
– ident: e_1_3_2_23_2
  doi: 10.1016/S0960-9822(99)80284-X
– ident: e_1_3_2_29_2
  doi: 10.1128/JVI.06157-11
– ident: e_1_3_2_12_2
  doi: 10.1073/pnas.0813223106
– ident: e_1_3_2_4_2
  doi: 10.1128/JVI.03219-12
– ident: e_1_3_2_2_2
  doi: 10.1097/00002030-199010000-00008
– ident: e_1_3_2_34_2
  doi: 10.1093/nar/18.12.3587
– ident: e_1_3_2_35_2
  doi: 10.1006/jmbi.1994.1542
– ident: e_1_3_2_42_2
  doi: 10.1074/jbc.M111.296772
– ident: e_1_3_2_20_2
  doi: 10.1016/S1097-2765(00)80056-8
– ident: e_1_3_2_44_2
  doi: 10.1089/hum.1995.6.10-1291
– ident: e_1_3_2_9_2
  doi: 10.1128/JVI.00242-09
– ident: e_1_3_2_38_2
  doi: 10.1128/JVI.02272-12
– ident: e_1_3_2_10_2
  doi: 10.1371/journal.ppat.1000856
– ident: e_1_3_2_15_2
  doi: 10.1371/journal.ppat.1000429
– ident: e_1_3_2_19_2
  doi: 10.1006/viro.1996.0491
– ident: e_1_3_2_27_2
  doi: 10.1128/JVI.02660-07
– ident: e_1_3_2_39_2
  doi: 10.1128/JVI.78.3.1069-1079.2004
– ident: e_1_3_2_46_2
  doi: 10.1073/pnas.1304288110
– ident: e_1_3_2_11_2
  doi: 10.1128/JVI.01795-10
– ident: e_1_3_2_6_2
  doi: 10.1016/j.chom.2008.03.001
– ident: e_1_3_2_40_2
  doi: 10.1016/j.jviromet.2006.06.019
– ident: e_1_3_2_13_2
  doi: 10.1371/journal.ppat.1003299
– ident: e_1_3_2_41_2
  doi: 10.1128/JVI.05933-11
– ident: e_1_3_2_47_2
  doi: 10.1056/NEJMoa1110187
– ident: e_1_3_2_18_2
  doi: 10.1128/JVI.05524-11
– ident: e_1_3_2_30_2
  doi: 10.1086/512088
– ident: e_1_3_2_5_2
  doi: 10.1038/nature06553
– ident: e_1_3_2_43_2
  doi: 10.1128/JVI.01699-10
– ident: e_1_3_2_28_2
  doi: 10.1084/jem.20090378
– ident: e_1_3_2_33_2
  doi: 10.1038/381661a0
– ident: e_1_3_2_7_2
  doi: 10.1016/j.tim.2010.06.010
– ident: e_1_3_2_37_2
  doi: 10.1128/jvi.70.2.809-819.1996
– ident: e_1_3_2_3_2
  doi: 10.1128/JVI.01844-08
– ident: e_1_3_2_25_2
  doi: 10.1073/pnas.0802203105
– ident: e_1_3_2_26_2
  doi: 10.1016/j.jtbi.2009.07.038
– ident: e_1_3_2_8_2
  doi: 10.1371/journal.ppat.1000450
– ident: e_1_3_2_31_2
  doi: 10.1128/jvi.59.2.284-291.1986
– ident: e_1_3_2_36_2
  doi: 10.1128/jvi.64.2.621-629.1990
– ident: e_1_3_2_45_2
  doi: 10.1371/journal.ppat.1000574
– ident: e_1_3_2_17_2
  doi: 10.1186/1742-4690-7-13
– ident: e_1_3_2_21_2
  doi: 10.1074/jbc.M300327200
– ident: e_1_3_2_32_2
  doi: 10.7326/0003-4819-152-12-201006150-00005
– ident: e_1_3_2_24_2
  doi: 10.1128/JVI.03230-13
– ident: e_1_3_2_14_2
  doi: 10.1016/j.chom.2009.10.004
– ident: e_1_3_2_22_2
  doi: 10.1074/jbc.274.47.33800
– reference: 23542380 - Proc Natl Acad Sci U S A. 2013 Apr 23;110(17):6626-33
– reference: 12746459 - J Biol Chem. 2003 Jul 25;278(30):28346-53
– reference: 19730691 - PLoS Pathog. 2009 Sep;5(9):e1000574
– reference: 10559275 - J Biol Chem. 1999 Nov 19;274(47):33800-6
– reference: 7520946 - J Mol Biol. 1994 Sep 2;241(5):651-62
– reference: 8590733 - Hum Gene Ther. 1995 Oct;6(10):1291-7
– reference: 18490657 - Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
– reference: 18256145 - J Virol. 2008 Apr;82(8):3952-70
– reference: 22072710 - J Biol Chem. 2012 Jan 2;287(1):58-67
– reference: 2261128 - AIDS. 1990 Oct;4(10):995-9
– reference: 22190722 - J Virol. 2012 Mar;86(5):2715-28
– reference: 2194165 - Nucleic Acids Res. 1990 Jun 25;18(12):3587-96
– reference: 19501037 - Cell Host Microbe. 2009 Jul 23;6(1):54-67
– reference: 14722262 - J Virol. 2004 Feb;78(3):1069-79
– reference: 19478868 - PLoS Pathog. 2009 May;5(5):e1000450
– reference: 17330784 - J Infect Dis. 2007 Apr 1;195(7):951-9
– reference: 19436700 - PLoS Pathog. 2009 May;5(5):e1000429
– reference: 19487424 - J Exp Med. 2009 Jun 8;206(6):1273-89
– reference: 23633949 - PLoS Pathog. 2013;9(4):e1003299
– reference: 22090097 - J Virol. 2012 Jan;86(2):757-72
– reference: 2404139 - J Virol. 1990 Feb;64(2):621-9
– reference: 19176632 - J Virol. 2009 Apr;83(8):3719-33
– reference: 21849457 - J Virol. 2011 Oct;85(20):10659-68
– reference: 8806575 - Virology. 1996 Sep 15;223(2):381-6
– reference: 8551619 - J Virol. 1996 Feb;70(2):809-19
– reference: 23323898 - N Engl J Med. 2013 Jan 17;368(3):218-30
– reference: 20980512 - J Virol. 2011 Jan;85(1):51-63
– reference: 18200009 - Nature. 2008 Jan 24;451(7177):425-30
– reference: 8649511 - Nature. 1996 Jun 20;381(6584):661-6
– reference: 18342597 - Cell Host Microbe. 2008 Apr 17;3(4):245-52
– reference: 24352444 - J Virol. 2014 Mar;88(5):2633-44
– reference: 19917496 - Cell Host Microbe. 2009 Nov 19;6(5):409-21
– reference: 20386718 - PLoS Pathog. 2010 Apr;6(4):e1000856
– reference: 10375528 - Curr Biol. 1999 Jun 17;9(12):622-31
– reference: 20167081 - Retrovirology. 2010;7:13
– reference: 19196977 - Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2868-73
– reference: 19660475 - J Theor Biol. 2009 Nov 21;261(2):341-60
– reference: 20926557 - J Virol. 2010 Dec;84(24):12958-70
– reference: 23325684 - J Virol. 2013 Mar;87(6):3549-60
– reference: 20688520 - Trends Microbiol. 2010 Sep;18(9):388-96
– reference: 20547906 - Ann Intern Med. 2010 Jun 15;152(12):778-85
– reference: 19515779 - J Virol. 2009 Aug;83(16):7931-47
– reference: 3016298 - J Virol. 1986 Aug;59(2):284-91
– reference: 23221546 - J Virol. 2013 Feb;87(4):2046-57
– reference: 9660940 - Mol Cell. 1998 Mar;1(4):565-74
– reference: 16876264 - J Virol Methods. 2006 Oct;137(1):125-33
SSID ssj0014464
Score 2.25472
Snippet Acute HIV-1 infection is characterized by a type I interferon response, resulting in the induction of host restriction factors. HIV-1 has evolved to counteract...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 5062
SubjectTerms Amino Acid Substitution
Antigens, CD - biosynthesis
Down-Regulation
GPI-Linked Proteins - biosynthesis
HIV Infections - virology
HIV-1 - genetics
HIV-1 - immunology
HIV-1 - isolation & purification
HIV-1 - physiology
Host-Pathogen Interactions
Human immunodeficiency virus 1
Human Immunodeficiency Virus Proteins - genetics
Humans
Longitudinal Studies
Polymorphism, Genetic
Simian immunodeficiency virus
Viral Regulatory and Accessory Proteins - genetics
Virus Release
Virus-Cell Interactions
Title Activities of Transmitted/Founder and Chronic Clade B HIV-1 Vpu and a C-Terminal Polymorphism Specifically Affecting Virion Release
URI https://www.ncbi.nlm.nih.gov/pubmed/24574397
https://www.proquest.com/docview/1514426273
https://www.proquest.com/docview/1520385015
https://pubmed.ncbi.nlm.nih.gov/PMC3993827
Volume 88
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbKIiQuiDflJSPBKUo3z7V73K1YuoUihLpVb5GdOEukNq2WVqhc-Vv8OGbsPNwtINhL1CRuoub7OjOOZ-Yj5HXf4xH4ZeZKnsduxATYwRhVUxnEFzJVviexwHn88Wh4Ho1m8azT-WllLW3Wspd-_21dyXVQhWOAK1bJ_geyzUXhAHwGfGELCMP2nzA-TrX2Q2Eax2q3syjW-v3lqdZLUiZDsuqAiwqYmXJOnOHZ1PWd6WpjWrU6A3dicmLmmA-3XSzh4aN4hhanzxHG-RbXftA4lhfOtLhE0nwGj1Wv7eyHt1g_Z7-xH4lcmKr28VIVDSWBoron6NW04A_qW6OpPcbMvvc9-wWFH7XpgFZNABorKw11XLRtpmzzjDPjUGsNg3MyFhkbnmJYZ5tszi1q9i37G3uVbVfVrtEH2vcTAdY-jKZnPS-MWOCaeliLMquF5kwQxThjY623bHIYP40HGNzxgN0gNwPGdJLAu1mTYIQT7ajuVY8_qi67CPihfWNsR13dZTc22pvwXM3btQKhyV1yp4KYHhs63iMdVd4nt4ym6fYB-dGSki5zapHysKIkBdLRipJUU5KeUE1JCpTUZwVtKUltSlKbkrShJDWUpBUlH5Lz07eTwdCtlD7cNOLh2hUpGBIfHUxf5YFUUkoV-Wmcs34m0pxnuZf5IlVeLqXvwYjQ4yoLjjLehz2ehY_IQbks1RNChZf6CryUirmMYk9KLmKWeUyIFGL5OOgSp37GSVq1wUc1lnmip8MBTwCcRIOT-GGXvGlGr0z7lz-Me1XDlYB9xkU3Uarl5msCEXWEqg_sr2MCXKCHyLxLHhuIm7vV3OgStgN-MwD7w--eKYsvuk98Rc-n1_7mM3K7_UM_Jwfry416ATH4Wr7UVP8FFKng5g
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activities+of+Transmitted%2FFounder+and+Chronic+Clade+B+HIV-1+Vpu+and+a+C-Terminal+Polymorphism+Specifically+Affecting+Virion+Release&rft.jtitle=Journal+of+virology&rft.au=Jafari%2C+Moein&rft.au=Guatelli%2C+John&rft.au=Lewinski%2C+Mary+K.&rft.date=2014-05-01&rft.pub=American+Society+for+Microbiology&rft.issn=0022-538X&rft.eissn=1098-5514&rft.volume=88&rft.issue=9&rft.spage=5062&rft.epage=5078&rft_id=info:doi/10.1128%2FJVI.03472-13&rft_id=info%3Apmid%2F24574397&rft.externalDocID=PMC3993827
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-538X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-538X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-538X&client=summon